SK Bioscience

Activity by year

202120222023202420252026

ExpansionContract

Jul 19, 2022CONTRACTSouth Korea$30.0M
SK Bioscience signs 39.4 billion won vaccine supply deal with Novavax
SK Bioscience announced a 39.4 billion won contract with Novavax to produce and supply COVID-19 vaccine in prefilled syringe (PFS) formulation.
SK Bioscience Novavax customer fnnews.com
Jun 21, 2021EXPANSIONAndong, North Gyeongsang Province, South Korea$133.0Mops 2024
SK Bioscience to invest 150 billion won in vaccine factory expansion in Andong
SK Bioscience signed an MOU with Gyeongbuk Province and Andong City to invest about 150 billion won by 2024 to expand production facilities at its L House vaccine factory in Andong, South Korea, and establish new platform facilities for mRNA and next-generation viral vectors.
SK Bioscience #Specialty Chemicals english.makalukhabar.com

Site	Largest	Latest
Andong, South Korea	$133.0M	2021-06-21

Customers

Loading…